2月24日 - ** 制药商BioMarin Pharmaceutical的BMRN.O股价盘前上涨~1.8%至68.25美元
** 奥本海默将 BMRN的评级从 "表现 "上调 至 "跑赢大盘"。
** 券商称，新管理层对运营效率、成本削减和研发投资回报的关注将 促进 BMRN 的收入增长
** 29家券商中有23家给予该股 "买入 "或更高评级，6家给予 "持有 "评级；其PT中值为95美元--数据由LSEG编制
** 截至上次收盘，该股今年累计上涨 ~3.8%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.